These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1311436)

  • 21. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats.
    Hamers FP; Brakkee JH; Cavalletti E; Tedeschi M; Marmonti L; Pezzoni G; Neijt JP; Gispen WH
    Cancer Res; 1993 Feb; 53(3):544-9. PubMed ID: 8425186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats.
    Sporel-Ozakat RE; Edwards PM; Van der Hoop RG; Gispen WH
    Eur J Pharmacol; 1990 Sep; 186(2-3):181-7. PubMed ID: 1963145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin neuropathy.
    Hol EM; Bär PR
    Neurology; 1995 Mar; 45(3 Pt 1):596; author reply 596-7. PubMed ID: 7898731
    [No Abstract]   [Full Text] [Related]  

  • 24. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
    Rose PG
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
    De Vos FY; Bos AM; Schaapveld M; de Swart CA; de Graaf H; van der Zee AG; Boezen HM; de Vries EG; Willemse PH
    Gynecol Oncol; 2005 Apr; 97(1):60-7. PubMed ID: 15790438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
    Nagy P; Kádasi L
    Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione.
    Bogliun G; Marzorati L; Cavaletti G; Frattola L
    Ital J Neurol Sci; 1992 Nov; 13(8):643-7. PubMed ID: 1336008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of peripheral nerve damage in leprosy.
    Richardus JH
    Lepr Rev; 1990 Dec; 61(4):404. PubMed ID: 2177816
    [No Abstract]   [Full Text] [Related]  

  • 30. Future opportunities in preventing cisplatin induced ototoxicity.
    van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
    Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 33. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma.
    Bohm S; Battista Spatti G; Di Re F; Oriana S; Pilotti S; Tedeschi M; Tognella S; Zunino F
    Anticancer Res; 1991; 11(4):1613-6. PubMed ID: 1746919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cisplatin].
    Millá A; Grau JJ; Estapé J
    Med Clin (Barc); 1983 Feb; 80(6):283-8. PubMed ID: 6345956
    [No Abstract]   [Full Text] [Related]  

  • 35. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-agent cis-platinum therapy for advanced ovarian cancer.
    Gershenson DM; Wharton JT; Herson J; Edwards CL; Rutledge FN
    Obstet Gynecol; 1981 Oct; 58(4):487-96. PubMed ID: 7024883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats.
    Hamers FP; Pette C; Neijt JP; Gispen WH
    Eur J Pharmacol; 1993 Mar; 233(1):177-8. PubMed ID: 8097161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Delayed platinum diamminodichloride toxicity in patients with germ tumors of the gonads].
    Germà Lluch JR; Izquierdo Font A; Barnadas Molins A; Arcusa Lanza MA; Ojeda González B
    Med Clin (Barc); 1984 Mar; 82(10):442-5. PubMed ID: 6538917
    [No Abstract]   [Full Text] [Related]  

  • 39. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer.
    Gogas H; Shapiro F; Aghajanian C; Fennelly D; Almadrones L; Hoskins WJ; Spriggs DR
    Gynecol Oncol; 1996 Apr; 61(1):22-6. PubMed ID: 8626111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.